EUVIMEDEUVIMED entdecken
Leserbrief

FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026

Changnian Li, Jingjing Pan

Clinical Lymphoma Myeloma and Leukemia · 2026-10

DOI: 10.1016/j.clml.2026.10.011 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Changnian Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: changnianli330@163.com. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: changnianli330@163.com.
  • First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: jingjingpan0929@163.com.

Zitieren

APA

Li, C., & Pan, J. (2026). FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.011

Vancouver

Li C, Pan J. FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.011

BibTeX
@article{Li2026,
  author = {Li, Changnian and Pan, Jingjing},
  title = {FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.10.011}
}
Kostenlos starten →